



**Co-founder Endré Balazs, M.D. addresses Boston Biomedical scientists, staff, friends and supporters at the 40th Anniversary of Independence gala dinner on November 13, 2008 at the Oakley Country Club. See page 2 for more photographs of the 40th Anniversary celebration.**

## At 40 years: looking back and ahead

Friends and supporters joined Boston Biomedical Research Institute staff, scientists and founders on November 13, 2008, to celebrate the Institute's 40th Anniversary of Independence.

The event, held at the Oakley Country Club in Watertown, MA, was sponsored by Millipore, BrillNeumann, Cambridge Trust Company, Lee Munder Capital Group, zFlo, Hyatt Regency Cambridge, Integrated DNA Technologies, and the Massachusetts Biotechnology Council.

After cocktails, guests took their seats for dinner and a journey through Boston Biomedical's past, present and future.

The keynote speaker, Dr. Leroy M. Hood, president of the Institute for Systems Biology in Seattle, Washington, spoke about the importance and unique contributions of independent research institutes like Boston Biomedical.

The founders of Boston Biomedical — Endré A. Balazs, M.D., and John Gergely, M.D., Ph.D. — told the audience about

the early years of the Institute and the contributions it has made to science and medicine since 1968.

Dr. Charles Emerson, Jr., director and senior scientist of Boston Biomedical, shared his hopes and plans for its future in cancer, cardiovascular, and neurodegenerative diseases.




**Director and Senior Scientist Charles Emerson, Jr., Ph.D., is flanked by co-founders Endré Balazs, M.D., and John Gergely, M.D., Ph.D., at Boston Biomedical's 40th anniversary event.**

## Did you know...

Today, 2 billion people are infected with the tuberculosis (TB) bacillus every year, 8.8 million people are newly diagnosed with active TB, and 1.6 million die from it. Dr. Henry Paulus, the Institute's deputy director, has devised a method for identifying protein splicing inhibitors, which are currently being tested as new therapeutics for multi-drug resistant TB.



One of our scientists, Martin Duennwald, Ph.D., is working with yeast — yes, the very yeast you would find in beer and bread. The single cell fungi serve as an excellent model organism because they are eukaryotic, that is, they have a nucleus enclosed within a membrane, like the cells in our bodies.




**Martin Duennwald with his yeast models of neurodegenerative diseases.**



We are working on cancer therapeutics for ovarian, prostate, breast, lung, pancreatic and brain cancer.



We are also researching adult stem cell-based therapies for muscular dystrophies, liver disease, lung disease (including emphysema and Alpha-1 deficiency), and diabetes.



## Contents

**40th anniversary celebrated..... 1**

**FSH Society partners with Boston Biomedical..... 2**

**Meet scientist Markus Hardt..... 3**